Advertisement

Topics

Blood Clot Concerns Prompt EU Restrictions For Pfizer's Xeljanz

07:50 EDT 17 May 2019 | Elsevier Business Intelligence

The European Medicines Agency's pharmacovigilance committee has launched a fresh review of Xeljanz and has also recommend...

Original Article: Blood Clot Concerns Prompt EU Restrictions For Pfizer's Xeljanz

NEXT ARTICLE

More From BioPortfolio on "Blood Clot Concerns Prompt EU Restrictions For Pfizer's Xeljanz"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...